ArticleClinical and experimental nephrology2026
Impact of frailty on prognosis in elderly patients with organ-threatening ANCA-associated vasculitis.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty has gained attention as an important prognostic factor in autoimmune diseases, but its clinical impact in organ-threatening ANCA-associated vasculitis (AAV) remains poorly understood. While recent advances in treatment have improved survival outcomes in AAV, maintaining quality of life (QOL) remains a challenge. This study investigated the impact of frailty on prognosis in elderly patients with severe AAV.
methodsWe retrospectively analyzed 23 newly diagnosed AAV patients with renal involvement. Frailty was assessed using the Clinical Frailty Scale (CFS). Patients were divided into robust and frail groups based on pre-AAV onset CFS scores. We compared clinical characteristics, treatment, outcomes, and CFS progression between groups. We also investigated predictors of serious adverse events (SAEs).
resultsNo significant difference in age was observed between the robust and frail groups. The frequency of rituximab, intravenous cyclophosphamide, and avacopan use was comparable between groups. Two deaths occurred during the 6-month follow-up period, both in the frail group. Serious adverse events (SAEs) occurred significantly more frequently in frail patients (66.7% vs. 9.1%, p < 0.01). Survival time analysis demonstrated a markedly higher SAE risk in the frail group (log-rank: p < 0.01, HR: 6.07). Patients who developed SAEs experienced progressive deterioration of frailty, whereas those who did not developed stable or improved frailty.
conclusionIn organ‑threatening AAV, frailty may be associated with an increased risk of severe adverse events and functional decline. These exploratory findings suggest a potential role for frailty assessment in initial risk stratification.
Indexed as
Identifiers
42319647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.